Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix for neuroendocrine tumors.
A review of the latest biopharma job cuts thus far in September and beyond.
The recent success of obesity treatments, particularly Ozempic (semaglutide) and Mounjaro (tirzepatide), has driven significant interest in glucagon-like peptide-1 receptor (GLP1R) targeting drugs. These therapies have witnessed a 595% increase in licensing deal value between 2019 and 2024 year-to-date (YTD), exceeding $6.2 billion in 2024 YTD alone.
Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes was linked to an elevated rate of temporary side effects in its initial test phase on humans.
The vaccine maker last month projected sales of $3 billion and $3.5 billion for this year, which will be its lowest annual revenue since Moderna launched its COVID-19 vaccine in late 2020 – the company’s first commercial product.
The investments are part of Lilly’s ongoing commitment to expand production, especially for its top-selling diabetes and obesity drugs, Mounjaro and Zepbound, respectively.
No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy. Experts weigh in on the path to profit for the treatment and the therapeutic class in general.
In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by 2031.
Roivant Sciences debuted its newest spinout venture Pulmovant, which will focus on the development of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease.
Candid Therapeutics, which is repositioning two antibodies for autoimmune indications, will be led by Ken Song who was previously CEO of RayzeBio and oversaw its $4.1 billion acquisition by Bristol Myers Squibb.